Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | TSPO | P30536 | 2/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971788 | 0.94 | FFAR1 (0.58) | FFAR1AKR1C3TSPOHSD17B2FFAR4 | |
| SCHEMBL4971865 | 0.91 | FFAR1 (0.56) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL4969516 | 0.89 | FFAR1 (0.47) | FFAR1AKR1C3TSPOHSD17B2FFAR4 | |
| SCHEMBL4971028 | 0.85 | FFAR1 (0.54) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL2085300 | 0.83 | FFAR1 (0.45) | FFAR1AKR1C3FFAR4MTNR1AMTNR1B | |
| SCHEMBL4971534 | 0.82 | FFAR1 (0.56) | FFAR1AKR1C3FFAR4KMT2AMEN1 | |
| SCHEMBL4969418 | 0.79 | FFAR1 (0.45) | FFAR1TSPOHSD17B2KMT2AMEN1 | |
| SCHEMBL4969366 | 0.79 | FFAR1 (0.52) | FFAR1FFAR4KMT2AMEN1 | |
| SCHEMBL4970657 | 0.79 | KCNH2 (0.42) | FFAR1AKR1C3TSPOHSD17B2KMT2A | |
| SCHEMBL4969393 | 0.78 | AKR1C3 (0.41) | FFAR1AKR1C3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781274-B1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2008-11-05 | — | — | EP | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | claimed |
| EP-1781274-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018325-A1 | NOVEL BIAROMATIC COMPOUNDS WHICH ACTIVATE RECEPTORS OF PPAR TYPE AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-23 | — | — | WO | claimed |
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207175-A1 | Biaromatic compound activators of PPARgamma receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | FFAR1 13/4885AKR1C3 737/4885TSPO 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.